

REFERENCES

- Patience, C., Takeuchi, Y., and Weiss, R.A. (1997) Infection of human cells by an endogenous retrovirus of pigs. *Nat. Med.* **3**, 282–286
- Wilson, C.A., Wong, S., Muller, J., Davidson, C.E., Rose, T.M., and Burd, P. (1998) Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. *J. Virol.* **72**, 3082–3087
- van der Laan, L.J.W., Lockey, C., Griffith, B.C., Frasier, F.S., Wilson, C.A., Onions, D.E., Hering, B.J., Long, Z., Otto, E., Torbett, B.E., and Salomon, D.R. (2000) Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. *Nature* **407**, 90–94
- Deng, Y.M., Tuch, B.E., and Rawlinson, W.D. (2000) Transmission of porcine endogenous retroviruses in severe combined immunodeficient mice xenotransplanted with fetal porcine pancreatic cells. *Transplantation* **70**, 1010–1016
- Switzer, W.M., Michler, R.E., Shanmugam, V., Matthews, A., Hussain, A.J., Wright, A., Sandstrom, P., Chapman, L.E., Weber, C., Safley, S., Denny, R.R., Navarro, A., Evans, V., Norin, A.J., Kwiatkowski, P., and Heneine, W. (2001) Lack of cross-species transmission of porcine endogenous retrovirus infection to nonhuman primate recipients of porcine cells, tissues, or organs. *Transplantation* **71**, 959–965
- Paradis, K., Langford, G., Long, Z., Heneine, W., Sandstrom, P., Switzer, W.M., Chapman, L.E., Lockey, C., Onions, D., and Otto, E. (1999) Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. *Science* **285**, 1236–1241
- Onishi, A., Iwamoto, M., Akita, T., Mikawa, S., Takeda, K., Awata, T., Hanada, H., and Perry, A.C. (2000) Pig cloning by microinjection of fetal fibroblast nuclei. *Science* **289**, 1188–1190
- Phelps, C.J., Koike, C., Vaught, T.D., Boone, J., Wells, K.D., Chen, S.H., Ball, S., Specht, S.M., Polejaeva, I.A., Monahan, J.A., Jobst, P.M., Sharma, S.B., Lamborn, A.E., Garst, A.S., Moore, M., Demetris, A.J., Rudert, W.A., Bottino, R., Bertera, S., Trucco, M., Starzl, T.S., Dai, Y., and Ayares, D.L. (2003) Production of alpha 1, 3-galactosyltransferase-deficient pigs. *Science* **299**, 411–414
- Oldmixon, B.A., Wood, J.C., Ericsson, T.A., Wilson, C.A., White-Scharf, M.E., Andersson, G., Greenstein, J.L., Schuurman, H.J., and Patience, C. (2002) Porcine endogenous retrovirus transmission characteristics of an inbred herd of miniature swine. *J. Virol.* **76**, 3045–3048
- Fiebig, U., Stephan, O., Kurth, R., and Denner, J. (2003) Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? *Virology* **307**, 406–413
- Qari, S.H., Magre, S., Garcia-Lerma, J.G., Hussain, A.I., Takeuchi, Y., Patience, C., Weiss, R.A., and Heneine, W. (2001) Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors. *J. Virol.* **75**, 1048–1053
- Stephan, O., Schwendemann, J., Specke, V., Tacke, S.J., Boller, K., and Denner, J. (2001) Porcine endogenous retroviruses (PERVs): Generation of specific antibodies, development of an immunoperoxidase assay (IPA) and inhibition by AZT. *Xenotransplantation* **8**, 310–316
- Oldmixon, B.A., Wood, J.C., Ericsson, T.A., Wilson, C.A., White-Scharf, M.E., Andersson, G., Greenstein, J.L., Schuurman, H.J., and Patience, C. (2002) Porcine endogenous retrovirus transmission characteristics of an inbred herd of miniature swine. *J. Virol.* **76**, 3045–3048
- Blusch, J.H., Patience, C., and Martin, U. (2002) Pig endogenous retroviruses and xenotransplantation. *Xenotransplantation* **9**, 242–251
- Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806–811
- Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* **101**, 25–33
- Matzke, M., Matzke, A.J., and Kooter, J.M. (2001) RNA: guiding gene silencing. *Science* **293**, 1080–1083
- Novina, C.D., Murray, M.F., Dykxhoorn, D.M., Beresford, P.J., Riess, J., Lee, S.K., Collman, R.G., Lieberman, J., Shankar, P., and Sharp, P.A. (2002) siRNA-directed inhibition of HIV-1 infection. *Nat. Med.* **8**, 681–686
- Miyagawa, S., Shirakura, R., Iwata, K., Nakata, S., Matsumiya, G., Izutani, H., Matsuda, H., Terado, A., Matsumoto, M., Nagasawa, S., and Seya, T. (1994) Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAF hybrid, on complement-mediated swine endothelial cell lysis. *Transplantation* **58**, 834–840
- Brummelkamp, T.R., Bernards, R., and Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**, 550–553
- Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**, 193–199
- Taylor, C.S., Takeuchi, Y., O'Hara, B., Johann, S.V., Weiss, R.A., and Collins, M.K. (1993) Mutation of amino acids within the gibbon ape leukemia virus (GALV) receptor differentially affects feline leukemia virus subgroup B, simian sarcoma-associated virus, and GALV infections. *J. Virol.* **67**, 6737–6741
- Kurihara, T., Miyazawa, T., Miyagawa, S., Tomonaga, K., Hazama, K., Yamada, J., Shirakura, R., and Matsuura, Y. (2003) Sensitivity to human serum of gammaretroviruses produced from pig endothelial cells transduced with glycosyltransferase genes. *Xenotransplantation* **10**, 562–568
- Hazama, K., Miyagawa, S., Miyazawa, T., Yamada, J., Tomonaga, K., Ota, M., Matsuda, H., and Shirakura, R. (2003) The significance of N-linked glycosylation in pig endogenous retrovirus infectivity. *Biochem. Biophys. Res. Commun.* **310**, 327–333
- Miyagawa, S., Kubo, T., Kusama, T., Nozaki, H., Moritan, T., Ahn, C., Kim, J.Y., Matsunami, K., Fukuta, D., and Shirakura, R. (2004) The feature of decay accelerating factor (DAF:CD55) on natural killer cell-mediated cytotoxicity. *J. Immunol.* **173**, 3945–3952
- Miyagawa, S., Yamada, J., Hazama, K., Yamamoto, A., Miyazawa, T., Tomonaga, K., and Shirakura, R. (2003) A study of the prevention of PERV infection by siRNA. *Xenotransplantation* **10**, 491
- Karlas, A., Kurth R., and Denner, J. (2004) Inhibition of porcine endogenous retroviruses by RNA interference: increasing the safety of xenotransplantation. *Virology* **325**, 18–23
- Olivetta, E., Pugliese, K., Bona, R., D'Aloja, P., Ferrantelli, F., Santarcangelo, A.C., Mattia, G., Verani, P., and Federico, M. (2000) cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails. *J. Virol.* **74**, 483–492



Original article

Cell-binding properties of the envelope proteins of porcine endogenous retroviruses

Rie Watanabe ^a, Takayuki Miyazawa ^{b,c,*}, Yoshiharu Matsuura ^a

^a Research Center for Emerging Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan

^b Host and Defense, PRESTO, Japan Science and Technology Agency (JST), 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan

^c Laboratory of Veterinary Infectious Diseases, Department of Applied Veterinary Science, Obihiro University of Agriculture and Veterinary Medicine, Nishi-2, Inada-cho, Obihiro, Hokkaido 080-8555, Japan

Received 10 December 2004; accepted 10 January 2005

Available online 22 March 2005

Abstract

To examine the binding properties of the envelope glycoproteins of porcine endogenous retrovirus subgroups A and B (PERV-A and PERV-B), we produced two forms of soluble envelope proteins, termed Env-ST and Env-SU, using a baculovirus expression system. Env-ST and Env-SU encompass one-third of the N-terminal and the entire surface unit (SU) of the envelope protein, respectively. Using these proteins, binding assays were performed in various mammalian cell lines. The binding properties of the Env-STs that contain the putative receptor binding domain (RBD) did not correlate with the susceptibility to the pseudotype viruses having PERV envelopes, whereas those of the Env-SUs correlated fairly well. These results suggested that the Env-SUs but not Env-STs interacted with their receptors in various cell lines. Interestingly, PERV-A Env-SU did not bind to a mink cell line (Mv1-Lu cells) that is highly susceptible to the PERV-A pseudotype virus. In addition, PERV-B Env-SU did not interfere with the PERV-B pseudotype virus on Mv1-Lu cells. These results suggest the existence of a cognate receptor-independent entry pathway as demonstrated in an immunodeficiency-inducing variant of feline leukemia virus FeLV. © 2005 Elsevier SAS. All rights reserved.

Keywords: Porcine endogenous retroviruses; Receptors; Xenotransplantation

1. Introduction

Pigs are considered the most suitable donor of organs or tissues in xenotransplantation to humans [1]. However, endogenous retroviruses are present in the porcine genome widely [2,3] and complete particles of porcine endogenous retroviruses (PERVs) [4], once thought to be uninfected to human

cells [5], have recently been shown to infect and replicate in human cells in vitro [6]. Therefore, the potential risk of PERV infection [7] has become an issue in pig-to-human xenotransplantation.

PERVs consist of three subgroups (PERV-A, B and C) according to the sequences of their envelope proteins, with both PERV-A and PERV-B exhibiting tropism to human cells in vitro [8]. PERVs are classified into the family Retroviridae, genus *Gammaretrovirus* [5], and gammaretroviral envelope proteins are synthesized as polyproteins that are proteolytically processed into surface unit (SU) and transmembrane glycoproteins to acquire infectivity [9]. The receptor binding domain (RBD) is present at the N-terminal of the SU envelope glycoprotein. The transmembrane envelope glycoprotein is responsible for the membrane anchoring and fusion activity that is required for viral entry into host cells [10]. Le Tissier et al. (1997) defined two variable regions (VRs), VRA and VRB, followed by a proline-rich region

Abbreviations: DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; FeLV, feline leukemia virus; GalV, gibbon ape leukemia virus; HEK, human embryonic kidney; MAb, monoclonal antibody; MLV, murine leukemia virus; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PERV, porcine endogenous retrovirus; PRR, proline-rich region; RBD, receptor binding domain; SDS, sodium dodecyl sulfate; Sf9, *Spodoptera frugiperda* 9; SU, surface unit; VR, variable region; X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside.

* Corresponding author. Tel: +81 155 49 5392; fax: +81 155 49 5394.

E-mail address: takavet@obihiro.ac.jp (T. Miyazawa).

(PRR) in the SU envelope of PERV based on analogy with the envelope of murine leukemia virus (MLV), a prototype of the gammaretroviruses. The RBD of MLV consists of VRA and VRB and plays a dominant role in the choice of receptor [11–13], while the PRR of MLV is considered to contribute to the envelope's conformation and fusogenicity [14,15].

The host ranges of PERVs have been well characterized by infection assays using pseudotype MLV harboring PERV envelopes and it has been revealed that various mammalian cell lines possess functional receptor molecules permitting pseudotype viral infections [16]. On the other hand, the basic properties of PERV envelope proteins are still unclear. In this study, to examine the binding properties of envelope glycoproteins for PERV receptors, we expressed two forms of soluble envelope protein, termed Env-ST and Env-SU, using a baculovirus expression system. Env-ST covered one-third of the N-terminal SU envelope protein containing VRA and VRB. Env-SU covered all of the SU of envelope protein. Using these proteins, binding and interference assays were performed in various mammalian cell lines.

2. Materials and methods

2.1. Cells

Mammalian cells, human embryonic kidney (HEK) 293, HeLa (human cervix adenocarcinoma), HT1080 (human fibrosarcoma), NIH3T3 (mouse embryonic fibroblast), *Mus dunni* (mouse fibroblast) and Mv1-Lu (mink lung) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St. Louis, MI, USA) supplemented with 10% fetal calf serum (FCS), penicillin (100 units/ml) and streptomycin (100 µg/ml). TELCeB/pFBPERV-A and TELCeB/pFBPERV-B cells were used as a source of PERV pseudotype viruses and maintained in DMEM. Both MOLT-4 (human T lymphoblast) and 3201 (feline thymic lymphoma) cells were maintained in RPMI 1640 medium supplemented with 10% FCS and antibiotics. An insect cell line *Spodoptera frugiperda* (*Sf*9) was cultured in TC100 insect medium (Sigma) supplemented with 10% FCS. Another insect cell line, High-Five™, derived from *Trichoplusia ni*, was cultured in EX-CELL™ 405 medium (JRH BIOSCIENCES, Lenexa, KS, USA) in the absence of FCS.

2.2. Construction of mammalian expression plasmids and production of recombinant baculoviruses

According to the alignment of the amino acid sequences of the PERV envelope proteins (Fig. 1a), two soluble envelope proteins were designed. The DNA fragments encoding the N-terminal (Env-ST) and entire region (Env-SU) of SU of envelopes (Fig. 1b) were amplified by polymerase chain reaction (PCR) from the envelope expression plasmids pFBPERV-A and pFBPERV-B [16] as templates. PCR was performed using platinum® *pfx* polymerase (Invitrogen, Bed-

ford, MA, USA) and the primers listed in Table 1. Amplified fragments were digested with *Xba*I and *Sac*II, and then cloned into *Xba*I/*Sac*II sites of pcDNA3.1/myc-His B (Invitrogen) to add myc and His tags at the C-terminal of the SU proteins. DNA fragments encoding Env-ST and Env-SU tagged with myc-His epitopes, were excised with *Eco*RI/*Pme*I digestion and cloned into *Eco*RI/*Pme*I sites of the vector pCAG to produce mammalian expression vectors, pCAG/Env-STs {pCAG/PERVA(ST) and pCAG/PERVB(ST)} and pCAG/Env-SUs {pCAG/PERVA(SU) and pCAG/PERVB(SU)}. These fragments were also cloned into *Eco*RI/*Bgl*III sites of the vector pSG5 (Stratagene, La Jolla, CA, USA), and then *env* sequences followed by the SV40 polyA tail signal were cut out by *Xba*I digestion and cloned into the *Xba*I site of the baculovirus transfer vector pVL1392 (Becton Dickinson (BD), San Jose, CA, USA) to produce transfer vectors termed pVL/PERVA(SU), pVL/PERVB(SU), pVL/PERVA(ST) and pVL/PERVB(ST). To obtain recombinant baculoviruses, AcPERVA(SU), AcPERVB(SU), AcPERVA(ST) and AcPERVB(ST), transfer vectors were transfected to *Sf*9 cells with linear BaculoGold™ (BD). The recombinant baculoviruses were purified by plaque purification and inoculated onto *Sf*9 cells to obtain stocks of virus with higher titers. The DNA fragment encoding Env-SU of the amphotropic MLV (MLV-A) envelope was amplified by PCR from the envelope expression plasmid pFBASALF [17]. The amplified fragment was cloned into pcDNA3.1/myc-His B and excised by *Bam*HI/*Pme*I digestion. This fragment was cloned into *Bam*HI/*Bgl*III sites of the vector pSG5 and excised by *Xba*I digestion to produce pVL/MLVA(SU) as described above. The recombinant baculovirus Ac/MLVA(SU) was obtained by co-transfection of pVL/MLVA(SU) and linear BaculoGold™.

2.3. Expression and immunoblot analyses of the recombinant proteins

Mammalian expression plasmids, pCAG/Env-SUs, were transfected to HEK293T cells using FuGENE6 transfection reagent (Roche, Basel, Switzerland). Forty-eight hours after transfection, the culture supernatants and cells were harvested. Culture supernatants were centrifuged at 3500 rpm for 5 min to clarify the cell debris. Cells were washed twice with ice-cold phosphate-buffered saline {PBS(-)}, lysed with a lysis buffer (10% Triton X-100, 10% glycerol, and 0.5% CHAPS), and then soluble fractions were collected.

Stocks of recombinant baculoviruses were inoculated onto HighFive™ cells at a multiplicity of infection of 10. One hour after infection, cells were washed and cultured in non-serum EXCELL™ 405 medium. Three days after infection, culture supernatants and cells were harvested as described above.

Each sample was subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and separated proteins were detected by immunoblotting using an anti-hexa-IIIs monoclonal antibody (MAb) (TECNIINE, Minneapolis, MN, USA) as described elsewhere.




Fig. 1. (a) Comparison of the amino acid sequences of envelope proteins of PERV-A, PERV-B and PERV-C. Identical amino acids are shown with a dot and gaps are indicated with a dash. Two VRs (VRA and VRB), PRR and putative PHQV motif are enclosed with boxes. The cleavage site between SU and transmembrane envelope glycoproteins is indicated with an arrowhead. (b) Schematic representation of a full-length PERV envelope protein (Full) and truncated soluble envelope proteins (Env-ST and Env-SU) used in this study.

Table 1
Oligonucleotide primers used for PCR

Forward	PERV Fwd	5'-GCTCTAGACCACCATGCATCCCACGTTAAGCTG-3'
	MLV-A Fwd	5'-GCTCTAGACCACCATGGCGCGTTCAACGCTCTC-3'
Reverse	PERV-A ST	5'-TCCC CGCGGTTCCATCTGAGTTTCTAATCTGAGGCG-3'
	PERV-A SU	5'-TCCC CGCGGTCITTTTGGCCGATATATCTATAG-3'
	PERV-B ST	5'-TCCC CGCGGGGTCCC ACTGCCACAGGGG-3'
	PERV-B SU	5'-TCCC CGCGGATAGTCATATTCATCAAGGACC-3'
	MLV-A SU	5'-TCCC CGCGGTCITTTATATTTGGTACGCTGTTCAAGC-3'

The PERV Fwd is a universal primer for all target sequences of PERVs. Underlines represent restriction enzyme recognition sites.

2.4. Deglycosylation analyses

Harvested protein samples were deglycosylated using endoglycosidases, EndoH and PNGaseF (New England Biolabs, Beverly, MA, USA), according to the manufacturer's instructions. In brief, samples were denatured by boiling for 10 min at 100 °C in the presence of 0.5% SDS and 1% β-mercaptoethanol. Then, reaction buffer and the endoglycosidase were added to the samples and incubated for 1 h at 37 °C. PNGaseF treatment was carried out in the presence of 1% Nonidet P-40. Following the deglycosylation, each sample was subjected to 12% SDS-PAGE and separated proteins were detected with the anti-His Mab.

2.5. Titration of PERV pseudotype viruses

The titration of PERV pseudotype viruses was performed as described previously [18] with a slight modification. In brief, target cells were seeded at a concentration of 2.5 × 10⁴ cells in 0.25 ml per well of 48-well plates the day before infection. Culture supernatants from producer cell lines were filtered through a 0.45 μm filter (Millipore, Bedford, MA, USA) and serially diluted. These diluted samples were inoculated onto target cells in the presence of 8 μg/ml polybrene. Four hours after inoculation, the cells were washed once and incubated with fresh medium for a further 2 days. Cells were

stained with 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-gal) and *lacZ*-positive foci were counted.

2.6. Binding assays of soluble envelope proteins

Target cells were detached from culture flasks by treatment with PBS(-) containing 0.05% EDTA. Approximately 10^6 cells were suspended in 500 μ l of culture medium, then mixed with an equal volume of culture supernatant from HighFive™ cells infected with recombinant or wild-type baculoviruses. The mixtures were incubated at 4 °C for 1 h with gentle rotation. After three washes with PBS(-) containing 1% FCS, the cells were incubated with 100 μ l of 1:200 diluted anti-tetra-His MAb (Qiagen, Hilden, Germany) for 1 h on ice and washed. Then, cells were incubated with 100 μ l of 1:200 diluted anti-mouse IgG (H + L) conjugated with phycoerythrin (Jackson ImmunoResearch, West Grove, PA, USA) for 1 h on ice. After washing, fluorescence intensity was analyzed with a cytofluorometer FACSCalibur (BD). Then, mean fluorescent intensity was read from histograms and relative binding intensity was calculated based on control mean fluorescent intensity.

2.7. Purification of Env-SU proteins and interference assays

Env-SU proteins of PERV-B and MLV-A were purified from culture supernatants of HighFive™ cells by using Ni-NTA agarose beads (Qiagen). In brief, 100 ml of supernatant was added to 500 μ l of 50% Ni-NTA slurry and incubated for 14 h at 4 °C with gentle rotation. Then, the beads were collected using an empty column and washed twice with a washing buffer (50 mM NaH₂PO₄, 300 mM NaCl, and 20 mM imidazole, pH 8.0). After the wash, Env-SU proteins were eluted with an elution buffer (50 mM NaH₂PO₄, 300 mM NaCl, and 250 mM imidazole, pH 8.0) and flow-through fractions were collected. The collected proteins were dialyzed to remove the imidazole and analyzed by SDS-PAGE to check their purity.

The interference assays of pseudotype viruses were performed as described previously [19] with a slight modification. In brief, Mv1-Lu cells were seeded at a concentration of 2.5×10^4 cells in 0.25 ml per well of 48-well plates the day before infection. The purified proteins were serially diluted and added to the target cells prior to infection. After 30 min of pre-incubation, DMEM containing 100 focus-forming units (ffu) of PERV-B or MLV-A pseudotype virus was inoculated onto the target cells. Four hours after inoculation, the cells were washed once and incubated with fresh DMEM for a further 2 days. Cells were stained with X-gal and *lacZ*-positive foci were counted.

3. Results

3.1. Alignment of the amino acid sequences of PERV envelope proteins

The alignment of the amino acid sequences of envelope proteins of PERV-A, PERV-B and PERV-C are shown in

Fig. 1a. There are two VRs, VRA and VRB, in the N terminus of the SU region followed by PRR. PRR has extensive variations and the sequence identity of this region is even lower than that of VRA.

3.2. Expression of recombinant envelope proteins

Culture supernatants and cell lysates of HEK293T cells transfected with expression plasmids and HighFive™ cells infected with recombinant baculoviruses were harvested. Each sample was separated by SDS-PAGE under reducing conditions, and then the separated proteins were detected by immunoblotting (Fig. 2). The Env-ST proteins of both PERV-A and PERV-B were detected in cell lysates and efficiently released into culture supernatants of HEK293T cells (Fig. 2a, upper panel). The approximate molecular weights were 27 kDa, coinciding with a previous report on MLV [20]. However, though Env-SU proteins from HEK293T were detected in the cell lysates, they were not released into culture supernatants efficiently (Fig. 2a, lower panel). On the other hand, in the baculovirus expression system, both Env-SU and Env-ST proteins were detected in the culture supernatants and cell lysates (Fig. 2b).

To examine the glycosylation-properties, the proteins from culture supernatants of HighFive™ cells infected with recombinant baculoviruses were deglycosylated by EndoH and PNGaseF. Immunoblot analyses after deglycosylation revealed that Env-ST and Env-SU were attached with carbohydrates after translation (Fig. 3). Env-ST proteins were attached with EndoH susceptible high-mannose-typed carbohydrates. On the other hand, almost all carbohydrates attached to Env-SU proteins were resistant to EndoH and partially digested by PNGaseF.

Deglycosylation analyses were also carried out using soluble envelope proteins expressed in HEK293T cells. Cell lysates of HEK293T cells transfected with expression plasmids were treated with endoglycosidases. Immunoblot analyses after deglycosylation showed the same glycosylation pattern with the baculovirus expression system (data not shown).




Fig. 2. Immunoblot analyses of Env-ST (upper panel) and Env-SU (lower panel) proteins expressed by mammalian (a) and baculovirus expression systems (b). (a) HEK293T cells were transfected with mammalian expression plasmids (pCAG) of envelopes of PERV-A (lane A) and PERV-B (lane B). pCAG empty plasmid was used as a control (lane Ct). (b) HighFive™ cells were infected with recombinant baculoviruses expressing envelopes of PERV-A (lane A) and PERV-B (lane B). The baculovirus AcNPV was used as a control (lane Ct).




Fig. 3. Immunoblot analyses of Env-ST (a) and Env-SU (b) proteins in the culture supernatants from HighFive™ cells after the treatment with endoglycosidases, EndoH (H) and PNGaseF (F). Soluble envelope proteins of PERV-A (lane A) and PERV-B (lane B) were digested with the endoglycosidases indicated at the top of each panel.

3.3. Susceptibilities of various mammalian cell lines to PERV pseudotype viruses

PERV pseudotype viruses were titrated in various mammalian cell lines (Table 2). Pseudotype viruses possessing Moloney MLV cores were used to avoid post-entry restriction [21]. Consistent with a previous report [16], Mv1-Lu and HEK293 cells were susceptible to both PERV-A and PERV-B pseudotype viruses. Murine cell lines, NIH3T3 and *M. dunni*, showed susceptibility to PERV-B but not to PERV-A pseudotype viruses. HEK293 cells persistently infected with PERV-A or PERV-B were resistant to superinfections of each pseudotype virus. Interestingly, the HEK293 cells infected with PERVs were significantly more susceptible to the pseudotype viruses of heterologous subtypes than uninfected HEK293 cells. Though the reason for the phenomenon is unknown at present, PERV may assist the infection of heterologous subtype viruses with each other.

3.4. Binding properties of soluble envelope proteins in mammalian cells

The binding assays were conducted on a PERV-susceptible cell line (HEK293) and unsusceptible cell line (MOLT-4) by using Env-ST and Env-SU proteins expressed by the recom-

binant baculoviruses (Fig. 4). PERV-B Env-ST efficiently bound to both HEK293 and MOLT-4 cells, whereas PERV-A Env-ST did not bind to either. In contrast, PERV-B Env-SU strongly bound to HEK293 but not to MOLT-4 cells, and PERV-A Env-SU bound to HEK293, but not to MOLT-4 cells. To know the binding specificity, we carried out binding assays on HEK293 cells persistently infected with PERV-A or PERV-B. Irrespective of the persistent infection of PERVs, PERV-A Env-ST did not bind to HEK293 cells and PERV-B Env-ST bound to HEK293 cells. On the other hand, Env-SU proteins of PERV-A and PERV-B did not bind to HEK293 cells infected with PERV-A (293/PERV-A) and PERV-B (293/PERV-B), respectively (Fig. 4).

The binding assays were extended to various mammalian cell lines and the relative binding intensity was calculated (Table 3). There was no binding of PERV-A Env-ST in the cell lines as observed in HEK293 and MOLT-4 cells. PERV-B Env-ST showed non-specific binding properties to non-susceptible cell lines such as 293/PERV-B and MOLT-4 cells. PERV-A Env-SU showed specific binding to all PERV-A-susceptible cell lines except for Mv1-Lu cells. Although PERV-A pseudotype virus infects Mv1-Lu cells very efficiently (Table 2), there was no binding between PERV-A Env-SU and Mv1-Lu cells. PERV-B Env-SU bound to various cell lines susceptible to the PERV-B pseudotype virus.

3.5. Interference of pseudotype viruses with soluble envelope proteins

The inhibition assays on HEK293 and Mv1-Lu cells were performed using purified Env-SUs of PERV-B and MLV-A. In HEK293 cells, MLV-A Env-SU specifically inhibited the infection of MLV-A pseudotype virus efficiently and PERV-B Env-SU also inhibited the infection of PERV-B pseudotype virus (about 70% reduction by addition of 10 µg/ml of purified PERV-B Env-SU) (data not shown). In Mv1-Lu cells, the infection of MLV-A pseudotype virus was efficiently inhibited by MLV-A Env-SU (Fig. 5a). This inhibition was specific because the envelope did not interfere with PERV-B pseudotype virus infection (Fig. 5b). However, Env-SUs of PERV-B and MLV-A did not interfere with PERV-B pseudotype virus on Mv1-Lu. These inhibition assays were repeated with crude Env-SU proteins from culture supernatants of HighFive™ cells infected with Ac/PERVB(SU) and Ac/MLVA(SU) and similar results were obtained (data not shown).

4. Discussion

The glycosylation of envelope protein is essential for the proper folding of receptor binding sites in human immunodeficiency virus [22,23]. In addition, in Friend MLV, secretion of Env-SU was prevented when N-linked oligosaccharide was eliminated [24]. Previously we found that PERV infection requires N-linked carbohydrates in the envelope pro-

Table 2

The titers of pseudotype virus in various target cells

Target cells	Source	Titer (ffu/ml) of <i>lacZ</i> pseudotype ^a	
		PERV-A	PERV-B
Mv 1-Lu	Mink	55,000	26,500
NIH3T3	Mouse	<10	150
<i>M. dunni</i>		<10	1300
3201	Feline	<10	<10
HEK293	Human	1000	200
293/PERV-A ^b		<10	3050
293/PERV-B ^b		6050	<10
HeLa		400	30
MOLT-4		<10	<10
HT1 080		<10	<10

^a Averages of titers expressed as ffu of *lacZ* pseudotype viruses in two independent experiments are shown.

^b HEK293 cells persistently infected with PERV-A or PERV-B.




Fig. 4. Binding properties of PERV envelope proteins to HEK293 (a) and MOLT-4 (b). HEK293 cells persistently infected with PERV-A (c) and PERV-B (d) were also used as target cells. The X-axis represents the fluorescence intensity of control (gray filled), PERV-A Env (dotted line) and PERV-B Env (broken line). The soluble envelope proteins used are indicated at the top of each panel.

teins [25]. Although there are differences in the glycosylation pathways between insect and mammalian cells [26], many groups have used recombinant glycoproteins expressed by baculovirus systems. By using the recombinant proteins, binding properties of envelope proteins of amphotropic MLV, dengue virus and feline leukemia virus (FeLV) have been investigated [19,27,28]. As the first step in this study, deglycosylation experiments were performed using two endoglycosidases (EndoH and PNGaseF) to reveal the glycosylation properties of the recombinant proteins with a bacu-

lovirus expression system. EndoH digests high-mannose-typed carbohydrates and PNGaseF digests both high-mannose-typed and complex-typed carbohydrates [29]. Immunoblot analyses after endoglycosidase treatments revealed that both Env-ST and Env-SU had been modified with carbohydrates. The carbohydrates of Env-ST proteins were completely removed by EndoH treatment, indicating that high-mannose-typed carbohydrates were attached to the proteins. On the other hand, the great majority of carbohydrates attached to Env-SU was resistant to EndoH and only partially removed by PNGaseF treatment, indicating that these proteins were modified with O-linked carbohydrates. The reason for this different modification is unclear at present. However, it is possible that the conformations of the truncated Env-ST proteins are different from those of Env-SU proteins, influencing the carbohydrate-modification in the cells. Previously, it had been reported that retroviral envelope glycoproteins were modified with both N-linked and O-linked carbohydrates [30,31]. Since we needed large amounts of soluble envelope proteins modified with carbohydrates for the assays, we used recombinant envelope proteins expressed by the baculovirus expression system.

First we used Env-ST proteins for the binding assays because Env-ST contains the putative RBD and Env-ST proteins have been used for binding assays in MLV studies [27]

Table 3
Relative binding intensities of PERV envelopes in various mammalian cells

Target cells	PERV-A ^a		PERV-B ^a	
	Env-ST	Env-SU	Env-ST	Env-SU
Mv1-Lu	-	-	++	++
NIH3T3	-	-	+	+
<i>Mus dunni</i>	-	-	++	+
3201	-	-	-	-
HEK293	-	+	+	+
293/PERV-A	-	-	+	+
293/PERV-B	-	+	+	-
HeLa	-	+	+	+
MOLT-4	-	-	++	-
HT1080	-	-	-	-

^a Represents relative binding intensity under 2.5; +, 2.5–10.0; ++, > 10.0. At least two independent experiments were carried out.




Fig. 5. Interference assays using purified Env-SU of MLV-A (a) and PERV-B (b). One hundred focus forming units of PERV-B (■) and MLV-A (▲) pseudotype viruses were inoculated onto the Mv1-Lu cells in the presence of serially diluted purified Env-SU proteins. Two days after infection, cells were stained with X-gal and *lacZ*-positive foci were counted.

and receptor cloning for PERV-A [32]. HEK293 and MOLT-4 cells were selected as representative target cells that showed high and no susceptibility to PERV pseudotype viruses, respectively. Contrary to our expectation, PERV-A Env-ST did not bind either cell line whereas PERV-B Env-ST bound both. These results suggest that the conformation of RBD might not be retained properly in the Env-ST form. Then, we also used Env-SU proteins in the binding assays. Env-SUs from both PERV-A and PERV-B bound to HEK293 cells but not to MOLT-4 cells, suggesting that there was a specific interaction between PERV Env-SUs and receptor molecules. The binding specificity was confirmed in assays using HEK293 cells persistently infected with PERVs. Previously, two molecules were cloned as cellular receptors for PERV-A from HeLa cells, and designated as HuPAR-1 and HuPAR-2 [32]. PERV-A preferred HuPAR-2 to HuPAR-1, and PERV-A Env-ST bound specifically to HuPAR-2 but not HuPAR-1 [32]. It is possible that PERV-A Env-ST binds specifically to HuPAR-2 but this binding does not reflect the natural condition. In the present study, HEK293 cells may predominantly express only HuPAR-1 since PERV-A Env-ST bound to HEK293 cells transfected with the expression plasmid for HuPAR-2 (data not shown). PERV-A Env-SU might have bound to HuPAR-1 expressed on HEK 293 cells.

Next, we applied the binding assays to various mammalian cell lines. The binding properties of PERV-A Env-SU correlated fairly well with the susceptibility to PERV-A pseudotype virus and those of PERV-B Env-SU completely coincided with the susceptibility to PERV-B pseudotype virus (Table 3). However, there was one exception; PERV-A Env-SU did not bind to Mv1-Lu cells, which are highly susceptible to the pseudotype virus. From the results obtained in HEK293 and 293/PERV-A, PERV-A Env-SU surely interacts with the PERV-A receptor(s). There are two possible explanations for this phenomenon. First, the affinity of PERV-A Env-SU prepared in this study for the PERV-A receptor(s) of minks was very low. Another possibility is that PERV-A infected the cells via an alternative pathway (i.e. cognate receptor-independent pathway) by virtue of the envelope protein of an endogenous retrovirus as reported in an immunodeficiency-inducing variant of FeLV [33,34].

Finally, we performed interference assays with the pseudotype viruses in HEK293 and Mv1-Lu cells by using purified

recombinant envelope proteins of PERV-B and MLV-A. In HEK293 cells, both recombinant proteins inhibited the infection of the homologous pseudotype viruses. However, PERV-B Env-SU failed to block the infection by PERV-B pseudotype virus on Mv1-Lu even at high concentrations. Although the reason for this phenomenon is unclear, PERV-B pseudotype virus might have infected the cells via an alternative pathway instead of through its cognate receptor(s) on Mv1-Lu. Quite recently Lavillette et al. [35] reported that both PERV-A and PERV-B can infect non-susceptible cells when the envelope protein of gibbon ape leukemia virus (GaLV) is added in trans. It is possible that Mv1-Lu cells express an endogenous retrovirus similar to GaLV. Actually, Mv1-Lu cells have been reported to express an endogenous retrovirus, although the characteristics of the virus are unknown [36]. GaLV utilizes Pit-1 as a receptor sharing with subgroup B FeLV (FeLV-B) [37] and we also reported that Mv1-Lu cells were partially resistant to FeLV-B pseudotype virus [38]. The Mv1-Lu cells seem not to express envelope protein of endogenous FeLV-related virus that interferes with FeLV-B because endogenous FeLV-dependent FeLV-T does not infect Mv1-Lu cells (data not shown). These data may suggest that Mv1-Lu cells express GaLV-like endogenous retrovirus [39] but not FeLV-like one. Molecular cloning of the endogenous retroviruses expressed in the Mv1-Lu cells is needed to elucidate the mechanism of PERV infection to the cells.

In this study we revealed that PERV Env-STs do not bind to PERV receptors specifically and that the entire region of SU Env is required for a specific binding. These properties are similar to those observed in xenotropic and polytropic MLVs but not those in ecotropic and amphotropic MLVs [13]. As our results suggested that both PERV-A and PERV-B infected Mv1-Lu cells via a cognate receptor-independent pathway, PERVs may infect non-susceptible cells efficiently by virtue of endogenous retrovirus expressed in humans. Further studies are required to verify this possibility and to evaluate the risks of PERV infections in the xenotransplantation of pig organs to humans.

Acknowledgements

We are grateful to Dr. Takeuchi (University College London, London, UK) for providing plasmids pFBPERV-A,

pFBPERV-B and pFBASALF, and TELCeB cells. This study was supported by grants from Host and Defence, PRESTO, Japan Science and Technology Agency (JST), Ministry of Education, Culture, Sports, Science and Technology of Japan, Ministry of Health, Labour and Welfare of Japan, and National Cardiovascular Center of Japan.

References

- [1] A. Dorling, K. Riesbeck, A. Warrens, R. Lechler, Clinical xenotransplantation of solid organs, *Lancet* 349 (1997) 867–871.
- [2] C. Herring, G. Quinn, R. Bower, N. Parsons, N.A. Logan, A. Brawley, et al., Mapping full-length porcine endogenous retroviruses in a large white pig, *J. Virol.* 75 (2001) 12252–12265.
- [3] J.-H. Lee, G.C. Webb, R.D.M. Allen, C. Moran, Characterizing and mapping porcine endogenous retroviruses in Westran pigs, *J. Virol.* 76 (2002) 5548–5556.
- [4] J.A. Armstrong, J.S. Porterfield, A.T. De Madrid, C-type virus particles in pig kidney cell lines, *J. Gen. Virol.* 10 (1971) 195–198.
- [5] G.J. Todaro, R.E. Benveniste, M.M. Lieber, C.J. Sherr, Characterization of a type C virus released from the porcine cell line PK(15), *Viol.* 58 (1974) 65–74.
- [6] C. Patience, Y. Takeuchi, R.A. Weiss, Infection of human cells by an endogenous retrovirus of pigs, *Nat. Med.* 3 (1997) 282–286.
- [7] J.P. Stoye, J.M. Coffin, The dangers of xenotransplantation, *Nat. Med.* 1 1100 (1995) 1468–1475.
- [8] P. Le Tissier, J.P. Stoye, Y. Takeuchi, C. Patience, R.A. Weiss, Two sets of human-tropic pig retrovirus, *Nature* 389 (1997) 681–682.
- [9] E.O. Freed, R. Risser, The role of envelope glycoprotein processing in murine leukemia virus infection, *J. Virol.* 61 (1987) 2852–2856.
- [10] J.A. Ragheb, W.F. Anderson, Uncoupled expression of Moloney murine leukemia virus envelope polypeptides SU and TM: a functional analysis of the role of TM domains in viral entry, *J. Virol.* 68 (1994) 3207–3219.
- [11] W. Koch, G. Hunsmann, R. Friedrich, Nucleotide sequence of the envelope gene of friend murine leukemia virus, *J. Virol.* 45 (1983) 1–9.
- [12] J.-L. Battini, J.M. Heard, O. Danos, Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses, *J. Virol.* 66 (1992) 1468–1475.
- [13] J.-L. Battini, O. Danos, J.M. Heard, Receptor-binding domain of murine leukemia virus envelope glycoproteins, *J. Virol.* 69 (1995) 713–719.
- [14] B.W. Wu, P.M. Cannon, E.M. Gordon, F.L. Hall, W.F. Anderson, Characterization of the proline-rich region of murine leukemia virus envelope protein, *J. Virol.* 72 (1998) 5383–5391.
- [15] D. Lavillette, M. Maurice, C. Roche, S.J. Russell, M. Sitbon, F.-L. Cosset, A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes, *J. Virol.* 72 (1998) 9955–9965.
- [16] Y. Takeuchi, C. Patience, S. Magre, R.A. Weiss, P.T. Banerjee, P. Le Tissier, et al., Host range and interference studies of three classes of pig endogenous retrovirus, *J. Virol.* 72 (1998) 9986–9991.
- [17] F.-L. Cosset, Y. Takeuchi, J.-L. Battini, R.A. Weiss, M.K.L. Collins, High-titer packaging cells producing recombinant retroviruses resistant to human serum, *J. Virol.* 69 (1995) 7430–7436.
- [18] Y. Takeuchi, F.-L. Cosset, P.J. Lachmann, H. Okada, R.A. Weiss, M.K.L. Collins, Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell, *J. Virol.* 68 (1994) 8001–8007.
- [19] I.K. Ramsey, N. Spibey, O. Jarrett, The receptor binding site of feline leukemia virus surface glycoprotein is distinct from the site involved in virus neutralization, *J. Virol.* 72 (1998) 3268–3277.
- [20] J.M. Heard, O. Danos, An amino-terminal fragment of the friend murine leukemia virus envelope glycoprotein binds the ecotropic receptor, *J. Virol.* 65 (1991) 4026–4032.
- [21] G. Towers, M. Bock, S. Martin, Y. Takeuchi, J.P. Stoye, O. Danos, A conserved mechanism of retrovirus restriction in mammals, *Proc. Natl. Acad. Sci. USA* 97 (2000) 12295–12299.
- [22] L. Dirckx, D. Lindemann, R. Ette, C. Manzoni, D. Moritz, J. Mous, Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity, *Virus Res.* 18 (1990) 9–20.
- [23] Y. Li, L. Luo, N. Rasool, C.Y. Kang, Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding, *J. Virol.* 67 (1993) 584–588.
- [24] J.-L. Battini, S.C. Kayman, A. Pinter, J.M. Heard, O. Danos, Role of N-linked glycosylation in the activity of the Friend murine leukemia virus SU protein receptor-binding domain, *Viol.* 202 (1994) 496–499.
- [25] K. Hazama, S. Miyagawa, T. Miyazawa, J. Yamada, K. Tomonaga, M. Ota, et al., The significance of N-linked glycosylation in pig endogenous retrovirus infectivity, *Biochem. Biophys. Res. Commun.* 310 (2003) 327–333.
- [26] D.L. Jarvis, Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production, *ViroLOGY* 310 (2003) 1–7.
- [27] J.-L. Battini, P. Rodrigues, R. Muller, O. Danos, J.M. Heard, Receptor-binding properties of a purified fragment of the 4070A amphotropic murine leukemia virus envelope glycoprotein, *J. Virol.* 70 (1996) 4387–4393.
- [28] Y. Chen, T. Maguire, R.M. Marks, Demonstration of binding of dengue virus envelope protein to target cells, *J. Virol.* 70 (1996) 8765–8772.
- [29] N.R. Thotakura, O.P. Bahl, Enzymatic deglycosylation of glycoproteins, *Methods Enzymol.* 138 (1987) 350–359.
- [30] A. Pinter, W.J. Honnen, O-linked glycosylation of retroviral envelope gene products, *J. Virol.* 62 (1998) 1016–1021.
- [31] H.B. Bernstein, S.P. Tucker, E. Hunter, J.S. Schutzbach, R.W. Compans, Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides, *J. Virol.* 68 (1994) 463–468.
- [32] T.A. Ericsson, Y. Takeuchi, C. Templin, G. Quinn, S.F. Farhadian, J.C. Wood, et al., Identification of receptors for pig endogenous retrovirus, *Proc. Natl. Acad. Sci. USA* 100 (2003) 6759–6764.
- [33] D.L. Wensel, W. Li, J.M. Cunningham, A virus-virus interaction circumvents the virus receptor requirement for infection by pathogenic retroviruses, *J. Virol.* 77 (2003) 3460–3469.
- [34] M.M. Anderson, A.S. Lauring, C.C. Burns, J. Overbaugh, Identification of a cellular cofactor required for infection by feline leukemia virus, *Science* 287 (2000) 1828–1830.
- [35] D. Lavillette, D. Kabat, Porcine endogenous retroviruses infect cells lacking cognate receptors by an alternative pathway: Implications for retrovirus evolution and xenotransplantation, *J. Virol.* 78 (2004) 8868–8877.
- [36] M. Barbacid, S.R. Tronick, S.A. Aaronson, Isolation and characterization of an endogenous type C RNA virus of mink (Mv1Lu) cells, *J. Virol.* 25 (1978) 129–137.
- [37] Y. Takeuchi, R.G. Vile, G. Simpson, B. O'Hara, M.K. Collins, R.A. Weiss, Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus, *J. Virol.* 66 (1992) 1219–1222.
- [38] R. Nakata, T. Miyazawa, Y.-S. Shin, R. Watanabe, T. Mikami, Y. Matsuura, Reevaluation of host ranges of feline leukemia virus subgroups, *Microbes Infect.* 5 (2003) 947–950.
- [39] J.J. Hanger, L.D. Bromham, J.J. McKee, T.M. O'Brien, W.F. Robinson, The nucleotide sequence of koala (*Phascolactos cinereus*) retrovirus: a novel type C endogenous virus related to gibbon ape leukemia virus, *J. Virol.* 74 (2000) 4264–4272.

●特集「異種移植」

ブタ内在性レトロウイルスと
異種移植

宮沢孝幸

帯広畜産大学畜産学部獣医学科応用獣医学講座

2005・10 発行
移 植 (Vol.40 No.5)
◁日本移植学会雑誌▷
別 刷

特集 「異種移植」

ブタ内在性レトロウイルスと
異種移植

宮沢孝幸

帯広畜産大学畜産学部獣医学科応用獣医学講座

はじめに

ヒトおよび類人猿と旧世界ザルでは、進化の過程で約3,000万年前に糖鎖を合成する酵素の一つである α -1,3ガラクトース転移酵素(α -1,3GT)の遺伝子が不活化された¹⁾。そのため、ヒトは α -ガラクトース(α -Gal)抗原を持たず、外来抗原として認識し、自然界に存在する α -Gal抗原の曝露により抗 α -Gal抗体が大量に誘導されている。この抗体は、他の動物由来のエンベロープウイルスの感染防御に役に立っている²⁾。他の動物の細胞で増殖したエンベロープウイルスは、エンベロープに α -Gal抗原を持ち、ヒトがこのウイルスに曝露されたとしても、抗 α -Gal抗体と補体により速やかにウイルスが中和され、感染は成立しにくいのである。

現在、臓器移植のための臓器不足の解消や、新しい細胞移植治療法の開発に向けて、ブタの臓器や細胞を異種間移植する方法が活発に研究されている³⁾。ブタの細胞は α -Gal抗原を大量に発現しているため、ヒトの抗 α -Gal抗体と補体を介する超急性拒絶反応が起こるが、これを抑えるために補体制御遺伝子や糖転移酵素遺伝子を導入したブタ、さらには α -1,3GTそのものをノックアウトしたブタなどが開発されている⁴⁾。しかし、そのような手法は移植を成立させる一方で、抗 α -Gal抗体を介したウイルスに対する自然抵抗性を減弱させてしまう。そのため、これらの遺伝子改変ブタからのウイルスが患者に感染し、さらにはヒト社会に

広まる危険性がある。

ヒトに感染する可能性があるブタのウイルスのうち最大の問題は、ブタ内在性レトロウイルス(porcine endogenous retrovirus: PERV)である⁵⁾。内在性レトロウイルスは生まれつきすべての体細胞のゲノムに存在するため、ブタから取り除くことは現時点では不可能である。1996年にヒトの細胞に感染するPERVが2種類(PERV-A, PERV-B)発見された(AとBはそれぞれ異なる受容体を認識する)⁶⁾。PERVはヒトの細胞で増殖はするが、一般にその増殖力は弱い。しかし、わずかな変異によりヒトに馴化したウイルスが生じたり、ヒトの内在性レトロウイルスと組み替わることで、より増殖性の高いウイルスが出現する可能性もある⁷⁾。PERVはブタでは病原性を持たないが、突然変異や組み換えにより、病原性を発現する可能性がある。そして、その感染は移植患者だけではなく、社会全体にも広がることも危惧される。従って、ブタを用いた異種間臓器移植の実用化には、PERVの制御が必要不可欠である。そのためには、PERVの産生抑制法の開発、感染メカニズムの解析および高感度検出系の確立が求められる(図1)。

PERVの考えられる制御法



PERVは、ブタのゲノムからmRNAとして転写され、mRNAからウイルス構成蛋白が合成され、最

最終的に感染性のあるウイルス粒子として放出される。PERVのウイルスゲノムは、ブタのゲノムのなかに50カ所以上存在するが、完全な感染ウイルス粒子として翻訳される mRNA 転写部位は数カ所である。しかしながら、PERVも含めたレトロウイルスは不完全な mRNA ゲノム同士で組み換えを起こし、不完全な部分をお互いに補い合うことがある。従って、不完全な mRNA ゲノム転写物と言えども、極力抑えることが重要である。

mRNA の転写物を抑える方法には、① RNA interference (RNA 干渉) を利用する方法、② リボザイムによる mRNA の破壊がある。これは、すでに確立されている手法であるが、実際には標的部位の選択が重要である。RNA 干渉を利用して、PERV の mRNA の発現を抑制したとの結果を、ドイツの Denner 博士らのグループがすでに発表している¹²⁾。国内でも同様の手法で、大阪大学と帯広畜産大学の研究グループが RNA 干渉を用いた方法による PERV mRNA の発現抑制を報告している¹³⁾。リボザイムによる mRNA の破壊については、PERV への応用例は国内外ともにまだ報告されていない。東京大学工学部の多比良和誠教授らが開発したマキシザイム (maxizyme) は、標的となる mRNA への特異性が高い上に分解効率も高いので、PERV への応用が期待できる^{14,15)}。

mRNA が産生されると、次いでウイルス蛋白が産生される。ウイルスのコア蛋白 (Gag 蛋白) のなかに PERV のゲノム RNA が組み込まれ、細胞外に放出さ

れる。レトロウイルスの Gag 蛋白の late assembly (L) domain は、細胞からウイルスが放出される際に重要である。L domain に結合する細胞側の蛋白である late domain interacting (LDI) 蛋白は、ウイルスの放出を助ける。LDI 蛋白のドミナントネガティブ変異体は、ウイルスの放出を阻害する。この現象を利用し、PERV の L domain に結合する細胞側の蛋白のドミナントネガティブ変異体を作製することにより、ウイルスのコア蛋白が産生されても、ウイルスが放出されないようにすることができる。

ウイルスの内部には、RNA のウイルスゲノムがパッケージングされる。通常のウイルスゲノム RNA はウイルス粒子のなかでコア蛋白によって守られている。しかし、このコア蛋白に RNA を分解する酵素を融合させることにより、取り込まれた RNA を積極的に分解させることが可能である。実際に同じガンマレトロウイルスで、この手法によりウイルスの産生を抑制に成功した例が報告されており、PERV への応用が期待される^{16,20)}。

ヒトは、NIH マウスに感染するマウス白血病ウイルス (N-tropic MLV) に対して抵抗性を有している²¹⁾。この抵抗性は *Ref-1* 因子と名付けられている。*Ref-1* 因子の本態は長らく不明であったが、最近それが TRIM5 α という分子であることが明らかとなった^{22,23)}。TRIM5 α は N-tropic MLV のコア蛋白と相互作用して、細胞内に侵入したウイルスのコアを分解経路に導くと考えられている (図 2)。TRIM5 α が認識するウイルス

図1 豚内在性レトロウイルス (PERV) の制御法の開発





図2 *Ref-1* (TRIM-5 α) の作用機序



コアの高次構造はまだ分かっていないが、PERVのコア蛋白に変異を導入することで、TRIM5 α に認識されるコア蛋白を作出できる可能性がある。TRIM5 α に認識されるPERV改変コア蛋白を遺伝子改変ブタに発現させれば、そのブタから産生されるPERV粒子は改変コア蛋白を取り込み、たとえヒトの細胞内に侵入したとしても、TRIM5 α に認識され分解されると考えられる。

これ以外にもPERVを制御する方法がいくつか考えられる。どの方法がPERVの制御において最も有効であるかは、今後の研究で明らかにされるであろう。トランスジェニック技術では、有効な方法を組み合わせることも可能である。従って将来的には、移植した臓器から産生されるヒトに感染するウイルス量を理論上ゼロにすることも可能であると思われる。しかし、ヒトに感染するPERVの産生を理論上「ゼロ」に抑えたとしても、安全性の検証には実験動物モデルが必要である。現在までに、PERV-Aの受容体のクローニングが成功しており²⁰、トランスジェニック技術によりマウスで感染実験モデルの作出が試みられている。今後PERV-Bの受容体のクローニングが成功すれば、ヒトに感染するすべてのPERV (PERV-A および PERV-B) の実験動物モデルも作出可能になるとと思われる。

最近、PERVの感染がギボンザル白血病ウイルス (GaLV) のエンベロープ蛋白により増強される現象が発見された²⁰。さらに、PERVの受容体が細胞表面上に存在しなくても、GaLVのEnvを利用して細胞内に侵入可能であることも明らかとなった。同様に、ミンクの肺由来細胞であるMv1-Lu細胞にPERV-Aが感染するときも、PERV受容体非依存性の感染が示唆されている²⁰。この現象を利用して、新たなPERV感染動物モデルの作出につながる可能性があり、今後の研究が期待される。

■ ■ ■ おわりに

今後数年以内に感染性のあるPERVが計算上産生されないブタが産出される可能性が高い。PERVの産生が完全に制御されれば、ブタを用いた異種移植への道は開かれるものと考えられる。PERVの産生が検出さ

れないブタの作出に成功したとしても、PERVの産生を完全に否定することはできない。また、PERV以外のヒトに感染性のある内在性レトロウイルスは、今のところ見つかってはいないが、存在しないことを証明することは事実上不可能である。この点については、PERVを理論上産生しないブタの臓器や組織、あるいは細胞を実際に感受性のある動物に接種して、安全性を検定する以外に現時点では方法はないと考えられる。

現時点で考えられるすべての可能性に対して万全の備えをし、万が一、PERVやその他の未知のウイルスがヒトに感染したときにも対応できるように、追跡システムの確立も重要であると思われる。

文 献

- 1) Galili U, Swanson K. Gene sequences suggest inactivation of α -1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. *Proc Natl Acad Sci USA* 1991; 88: 7401-7404.
- 2) Takeuchi Y, Porter CD, Strahan KM, *et al.* Sensitization of cells and retroviruses to human serum by (α 1- 3) galactosyltransferase. *Nature* 1996; 6560: 85-88.
- 3) Cooper DK, Ye Y, Rolf LLJ, *et al.* The pig as potential organ donor for man. In: Cooper DK, Kemp E, Reemtsma K, White DJG, editors, *Xenotransplantation*, Heidelberg: Springer, 1991; 481-500.
- 4) Byrne GW, McCurry KR, Kagan D, *et al.* Protection of xenogenic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice. *Transplantation* 1995; 60: 1149-1156.
- 5) Miyagawa S, Shirakura R, Matsumiya G, *et al.* Possibility of prevention of hyperacute rejection by DAF and CD59 in xenotransplantation. *Transplant Proc* 1994; 26: 1235-1238.
- 6) Phelps CJ, Koike C, Vaught TD, *et al.* Production of α 1,3-galactosyltransferase-deficient pigs. *Science* 2003; 299: 411-414.
- 7) Dai Y, Vaught TD, Boone J, *et al.* Targeted disruption

- of the α 1,3-galactosyltransferase gene in cloned pigs. *Nat Biotechnol* 2002; 20: 251-255.
- 8) Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus in pigs. *Nat. Med* 1997; 3: 282-286.
- 9) Le Tissier P, Stoye JP, Takeuchi Y, *et al.* Two sets of human-tropic pig retrovirus. *Nature* 1997; 389: 681-682.
- 10) Magre S, Takeuchi Y, Bartosch B. Xenotransplantation and pig endogenous retrovirus. *Rev Med Virol* 2003; 13: 311-329.
- 11) Bartosch B, Stefanidis D, Myers R, *et al.* Evidence and consequence of porcine endogenous retrovirus recombination. *J Virol* 2004; 78: 13880-13890.
- 12) Karlas A, Kurth R, Denner J. Inhibition of porcine endogenous retroviruses by RNA interference: increasing the safety of xenotransplantation. *Virology* 2004; 325: 18-23.
- 13) Miyagawa S, Nakatsu S, Nakagawa T, *et al.* Prevention of PERV infections in pig to human xenotransplantation by tyc RNA interference silences gene. *J Biochem* 2005; 137: 503-508.
- 14) Iyo M, Kawasaki H, Taira K. Allosterically controllable maxizymes for molecular gene therapy. *Curr Opin Mol Ther* 2002; 4: 154-165.
- 15) Oshima K, Kawasaki H, Soda Y, *et al.* Maxizymes and small hairpin-type RNAs that are driven by a tRNA promoter specifically cleave a chimeric gene associated with leukemia in vitro and in vivo. *Cancer Res.* 2003; 63: 6809-6814.
- 16) Kikonyogo A, Bouamr F, Vana ML, *et al.* Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. *Proc. Natl Acad Sci USA* 2001; 98: 11199-11204.
- 17) Vana ML, Tang Y, Chen A, *et al.* Role of Nedd4 and ubiquitination of Rous sarcoma virus Gag in budding of virus-like particles from cells. *J Virol* 2004; 78: 13943-13953.
- 18) VanBrocklin M, Federspiel MJ. Capsid-targeted viral inactivation can eliminate the production of infectious murine leukemia virus in vitro. *Virology* 2000; 267: 111-123.
- 19) Schumann G, Qin L, Rein A, Natsoulis G, *et al.* Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures. *J Virol* 1996; 70: 4329-4337.
- 20) VanBrocklin M, Ferris AL, Hughes SH, *et al.* Expression of a murine leukemia virus Gag-Escherichia coli RNase HI fusion polyproteins significantly inhibits viral spread. *J Virol* 1997; 71: 3312-3318.
- 21) Schumann G, Hermankova M, Cannon K, *et al.* Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo. *J Virol* 2001; 75: 7030-7041.
- 22) Towers G, Bock M, Martin S, *et al.* A conserved mechanism of retrovirus restriction in mammals. *Proc Natl Acad Sci USA* 2000; 97: 12295-12299.
- 23) Stremlau M, Owens CM, Perron MJ, *et al.* The cytoplasmic body component TRIM5 α restricts HIV-1 infection in Old World monkeys. *Nature* 2004; 427: 848-853.
- 24) Hatzioannou T, Perez-Caballero D, Yang A, *et al.* Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5 α . *Proc Natl Acad Sci USA* 2004; 101: 10774-10779.
- 25) Ericsson TA, Takeuchi Y, Templin C, *et al.* Identification of receptors for pig endogenous retrovirus. *Proc Natl Acad Sci USA* 2003; 100: 6759-6764.
- 26) Lavillette D, Kabat D. Porcine endogenous retroviruses infect cells lacking cognate receptors by an alternative pathway: implications for retrovirus evolution and xenotransplantation. *J Virol* 2004; 78: 8868-8877.
- 27) Watanabe R, Miyazawa T, Matsuura Y. Cell-binding properties of the envelope proteins of porcine endogenous retroviruses. *Microbes Infect* 2005; 7: 658-665.